L-92™ CLINICAL STUDIES
Kato S, Hirota T, Tominaga H. Lactobacillus acidophilus strain L-92™ mitigates skin inflammation in dogs with suspected allergy. Poster presented at International Scientific Conference on Probiotics and Probiotics; June 2014; Budapest, Hungary.
Topic: Does L-92™ improve skin condition in dogs clinically presenting skin inflammation?
Background: Previously, a number of studies have investigated the efficacy of the Lactobacillus acidophilus strain L-92™ in the treatment of Japanese cedar pollen allergy, perennial allergic rhinitis, and atopic dermatitis in human subjects. The efficacy of L-92™ in inhibiting allergy in dogs remains to be elucidated. This study investigates the efficacyof L-92™ to mitigate skin inflammation in dogs with suspected allergy.
Study Design: A population of dogs (n=36) meeting selection criteria 1) presenting skin inflammation with suspected allergy; 2) > 25% CD4 T cell population presenting CCR4+ status, were divided into two groups without significant difference in age, body weight, or percentage of CCR4+ cells.
Dosage: 20.7mg L-92™/day
Results: The L-92™ treatment group presented significantly lower scores of skin lesion area compared to the control group after a 4 week treatment period. Additionally, following 4 weeks of treatment with L-92™, the treatment group presented significantly lower scores of skin sensitivity, a significantly lower increase in CCR4+ cells compared to control, and a significant reduction in concentrations of allergen-specific IgE antibodies compared to the control. At 8 weeks no significant difference in the fecal microbiota population diversity between control and L-92™ treatment groups was observed.
Conclusion: These data support the efficacy of L-92™ treatment in dogs presenting skin inflammation